

# A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

NCT00967785

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 1, Phase 2
<b>Sponsor</b>	National Institute of Allergy and Infectious Diseases (NIAID)
<b>Enrollment</b>	20 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Clinical diagnosis of WHIMS and documented severe infection
  - Must be greater than or equal to 18 and less than or equal to 75 years of age
  - Willingness to interrupt medications to raise the white count (WBC) such as G-CSF or GM-CSF for at least 2 days before and while on the study drug
  - Must not be pregnant or breastfeeding
  - Must have a personal physician
- ... and 7 more (see full listing online)

### Exclusion (10)

- Absence of a diagnosis of WHIMS
  - Patient is less than 18 years old
  - Absence of a documented history of severe infection
  - Neutropenia due to maturation defects in the myeloid lineage or that the PI feels is unlikely to benefit from this medication
  - Pregnant women or breastfeeding
- ... and 5 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States